Responsibility in Drug Advertising Act of 2019
This bill prohibits direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.| Action Date | Type | Text | Source |
|---|---|---|---|
| 2019-07-31 | Committee | Referred to the Subcommittee on Health. | House committee actions |
| 2019-07-30 | IntroReferral | Referred to the House Committee on Energy and Commerce. | House floor actions |
| 2019-07-30 | IntroReferral | Introduced in House | Library of Congress |